Published in Proteomics on January 01, 2013
shRNA library screening identifies nucleocytoplasmic transport as a mediator of BCR-ABL1 kinase-independent resistance. Blood (2015) 0.93
Manumycin induces apoptosis in prostate cancer cells. Onco Targets Ther (2014) 0.81
Protein Z: A putative novel biomarker for early detection of ovarian cancer. Int J Cancer (2016) 0.77
Chemical Proteomic Approaches Targeting Cancer Stem Cells: A Review of Current Literature. Cancer Genomics Proteomics (2017) 0.75
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08
Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood (2002) 6.64
Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction. Blood (2006) 4.41
Activation of p53 by SIRT1 inhibition enhances elimination of CML leukemia stem cells in combination with imatinib. Cancer Cell (2012) 2.96
A small proportion of mesenchymal stem cells strongly expresses functionally active CXCR4 receptor capable of promoting migration to bone marrow. Blood (2004) 2.90
Cancer stem cell definitions and terminology: the devil is in the details. Nat Rev Cancer (2012) 2.76
Systems-level dynamic analyses of fate change in murine embryonic stem cells. Nature (2009) 2.70
Nilotinib exerts equipotent antiproliferative effects to imatinib and does not induce apoptosis in CD34+ CML cells. Blood (2007) 2.68
Multiple reaction monitoring to identify sites of protein phosphorylation with high sensitivity. Mol Cell Proteomics (2005) 2.26
BCR-ABL enhances differentiation of long-term repopulating hematopoietic stem cells. Blood (2010) 2.17
Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival. Blood (2011) 2.11
Altered microenvironmental regulation of leukemic and normal stem cells in chronic myelogenous leukemia. Cancer Cell (2012) 2.08
Inactivation of HOXA genes by hypermethylation in myeloid and lymphoid malignancy is frequent and associated with poor prognosis. Clin Cancer Res (2007) 2.08
Eight-channel iTRAQ enables comparison of the activity of six leukemogenic tyrosine kinases. Mol Cell Proteomics (2007) 2.08
Responsiveness of the Neck Disability Index in patients with mechanical neck disorders. Spine J (2009) 1.94
Quantitative proteomics reveals posttranslational control as a regulatory factor in primary hematopoietic stem cells. Blood (2006) 1.92
Hypusination of eukaryotic initiation factor 5A (eIF5A): a novel therapeutic target in BCR-ABL-positive leukemias identified by a proteomics approach. Blood (2006) 1.85
Targeting primitive chronic myeloid leukemia cells by effective inhibition of a new AHI-1-BCR-ABL-JAK2 complex. J Natl Cancer Inst (2013) 1.75
PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells. J Clin Invest (2013) 1.72
How I manage priapism in chronic myeloid leukaemia patients. Br J Haematol (2012) 1.70
Microenvironmental protection of CML stem and progenitor cells from tyrosine kinase inhibitors through N-cadherin and Wnt-β-catenin signaling. Blood (2013) 1.70
Alpha1-acid glycoprotein expressed in the plasma of chronic myeloid leukemia patients does not mediate significant in vitro resistance to STI571. Blood (2002) 1.68
Megakaryocytes assemble podosomes that degrade matrix and protrude through basement membrane. Blood (2013) 1.65
Microfluidic single cell arrays to interrogate signalling dynamics of individual, patient-derived hematopoietic stem cells. Lab Chip (2009) 1.61
Effective and selective inhibition of chronic myeloid leukemia primitive hematopoietic progenitors by the dual Src/Abl kinase inhibitor SKI-606. Blood (2007) 1.60
Regulation of embryonic and induced pluripotency by aurora kinase-p53 signaling. Cell Stem Cell (2012) 1.54
Early prediction of success or failure of treatment with second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia. Haematologica (2009) 1.50
A randomized phase 2 trial of bevacizumab with or without daily low-dose interferon alfa-2b in metastatic malignant melanoma. Ann Surg Oncol (2007) 1.49
Cancerous inhibitor of PP2A (CIP2A) at diagnosis of chronic myeloid leukemia is a critical determinant of disease progression. Blood (2011) 1.46
Functional ABCG2 is overexpressed on primary CML CD34+ cells and is inhibited by imatinib mesylate. Blood (2006) 1.43
Quantitative proteomic analysis using isobaric protein tags enables rapid comparison of changes in transcript and protein levels in transformed cells. Mol Cell Proteomics (2005) 1.42
BMS-214662 potently induces apoptosis of chronic myeloid leukemia stem and progenitor cells and synergizes with tyrosine kinase inhibitors. Blood (2007) 1.40
PEDRo: a database for storing, searching and disseminating experimental proteomics data. BMC Genomics (2004) 1.34
Markers of disease severity in chronic obstructive pulmonary disease. Pulm Pharmacol Ther (2005) 1.33
Bortezomib induces apoptosis in primitive chronic myeloid leukemia cells including LTC-IC and NOD/SCID repopulating cells. Blood (2010) 1.33
Punish the parent not the progeny. Blood (2004) 1.32
Interleukin-3-mediated cell survival signals include phosphatidylinositol 3-kinase-dependent translocation of the glucose transporter GLUT1 to the cell surface. J Biol Chem (2003) 1.31
SRC-induced disassembly of adherens junctions requires localized phosphorylation and degradation of the rac activator tiam1. Mol Cell (2009) 1.30
Effects of dasatinib on SRC kinase activity and downstream intracellular signaling in primitive chronic myelogenous leukemia hematopoietic cells. Cancer Res (2008) 1.30
Intermittent exposure of primitive quiescent chronic myeloid leukemia cells to granulocyte-colony stimulating factor in vitro promotes their elimination by imatinib mesylate. Clin Cancer Res (2006) 1.29
A sensitive mass spectrometric method for hypothesis-driven detection of peptide post-translational modifications: multiple reaction monitoring-initiated detection and sequencing (MIDAS). Nat Protoc (2009) 1.26
Simultaneous analysis of relative protein expression levels across multiple samples using iTRAQ isobaric tags with 2D nano LC-MS/MS. Nat Protoc (2010) 1.26
Chronic myeloid leukaemia: an investigation into the role of Bcr-Abl-induced abnormalities in glucose transport regulation. Oncogene (2005) 1.25
Transcriptional analysis of quiescent and proliferating CD34+ human hemopoietic cells from normal and chronic myeloid leukemia sources. Stem Cells (2007) 1.24
A novel mechanism for BCR-ABL action: stimulated secretion of CCN3 is involved in growth and differentiation regulation. Blood (2006) 1.24
In vivo monitoring of tissue pharmacokinetics of liposome/drug using MRI: illustration of targeted delivery. Magn Reson Med (2004) 1.20
Quantitative proteomics analysis demonstrates post-transcriptional regulation of embryonic stem cell differentiation to hematopoiesis. Mol Cell Proteomics (2007) 1.19
Melanoma cells exhibit variable signal transducer and activator of transcription 1 phosphorylation and a reduced response to IFN-alpha compared with immune effector cells. Clin Cancer Res (2007) 1.16
Personalized synthetic lethality induced by targeting RAD52 in leukemias identified by gene mutation and expression profile. Blood (2013) 1.16
Rac2-MRC-cIII-generated ROS cause genomic instability in chronic myeloid leukemia stem cells and primitive progenitors. Blood (2012) 1.16
THOC5/FMIP, an mRNA export TREX complex protein, is essential for hematopoietic primitive cell survival in vivo. BMC Biol (2010) 1.16
Kill one bird with two stones: potential efficacy of BCR-ABL and autophagy inhibition in CML. Blood (2011) 1.16
Global effects of BCR/ABL and TEL/PDGFRbeta expression on the proteome and phosphoproteome: identification of the Rho pathway as a target of BCR/ABL. J Biol Chem (2004) 1.15
Genomic instability may originate from imatinib-refractory chronic myeloid leukemia stem cells. Blood (2013) 1.13
The Functional Movement Screen: a reliability study. J Orthop Sports Phys Ther (2012) 1.13
The antiproliferative activity of kinase inhibitors in chronic myeloid leukemia cells is mediated by FOXO transcription factors. Stem Cells (2014) 1.13
Senior adult oncology clinical practice guidelines in oncology. J Natl Compr Canc Netw (2005) 1.09
Therapeutic targets in chronic myeloid leukaemia. Hematol Oncol (2007) 1.09
Chemodosimetry of in vivo tumor liposomal drug concentration using MRI. Magn Reson Med (2006) 1.08
Is serum or plasma more appropriate for intersubject comparisons in metabolomic studies? An assessment in patients with small-cell lung cancer. Anal Chem (2011) 1.07
Targeting hedgehog in hematologic malignancy. Blood (2012) 1.05
Evolving molecular therapy for chronic myeloid leukaemia--are we on target? Hematology (2005) 1.04
Markers of exacerbation severity in chronic obstructive pulmonary disease. Respir Res (2006) 1.04
Relative quantification in proteomics: new approaches for biochemistry. Trends Biochem Sci (2006) 1.02
Pilot study of rosiglitazone therapy in women with breast cancer: effects of short-term therapy on tumor tissue and serum markers. Clin Cancer Res (2007) 1.02
Gene expression profiling reveals similarities between the in vitro and in vivo responses of immune effector cells to IFN-alpha. Clin Cancer Res (2008) 1.02
Lineage tracing of Pf4-Cre marks hematopoietic stem cells and their progeny. PLoS One (2012) 1.01
The application of a hypothesis-driven strategy to the sensitive detection and location of acetylated lysine residues. J Am Soc Mass Spectrom (2007) 1.01
Second-generation tyrosine kinase inhibitors improve the survival of patients with chronic myeloid leukemia in whom imatinib therapy has failed. Haematologica (2011) 1.00
The hOCT1 SNPs M420del and M408V alter imatinib uptake and M420del modifies clinical outcome in imatinib-treated chronic myeloid leukemia. Blood (2012) 0.99
Oleoyl serine, an endogenous N-acyl amide, modulates bone remodeling and mass. Proc Natl Acad Sci U S A (2010) 0.99
Proteomics techniques and their application to hematology. Blood (2004) 0.99
Autophagy in blood cancers: biological role and therapeutic implications. Haematologica (2013) 0.99
Prospective randomized clinical trial comparing intradermal, intraparenchymal, and subareolar injection routes for sentinel lymph node mapping and biopsy in breast cancer. Ann Surg Oncol (2006) 0.99
Heterogeneity of neoplastic stem cells: theoretical, functional, and clinical implications. Cancer Res (2013) 0.98
Autocrine TNF-α production supports CML stem and progenitor cell survival and enhances their proliferation. Blood (2013) 0.98
FGFR3 regulates brain size by controlling progenitor cell proliferation and apoptosis during embryonic development. Dev Biol (2005) 0.98
Concise review: Telomere biology in normal and leukemic hematopoietic stem cells. Stem Cells (2007) 0.97
Concise review: cancer cells escape from oncogene addiction: understanding the mechanisms behind treatment failure for more effective targeting. Stem Cells (2014) 0.96
Developmental fate determination and marker discovery in hematopoietic stem cell biology using proteomic fingerprinting. Mol Cell Proteomics (2007) 0.96
Expression of STAT1 and STAT2 in malignant melanoma does not correlate with response to interferon-alpha adjuvant therapy. Cancer Immunol Immunother (2005) 0.96
Systematic proteome and transcriptome analysis of stem cell populations. Cell Cycle (2006) 0.95
DNMT inhibitors reverse a specific signature of aberrant promoter DNA methylation and associated gene silencing in AML. Genome Biol (2014) 0.95
Hif-2α is not essential for cell-autonomous hematopoietic stem cell maintenance. Blood (2013) 0.95